|Trade names||Cardene, others|
|Other names||Nicardipine hydrochloride|
|Drug class||Calcium channel blocker (dihydropyridine)|
|Main uses||High blood pressure, heart related chest pain|
|Side effects||Swelling, headache, palpations, low blood pressure|
|By mouth, intravenous|
|Elimination half-life||8.6 hours|
|Chemical and physical data|
|Molar mass||479.533 g·mol−1|
|3D model (JSmol)|
|Melting point||136–138 °C (277–280 °F)|
Nicardipine, sold under the brand name Cardene among others, is a medication used to treat high blood pressure and heart related chest pain. It is also used for Raynaud's phenomenon. It is given by mouth and injected into a vein.
Common side effects include swelling, headache, palpations, and low blood pressure. It should not be used in those with severe aortic stenosis. It may be used in pregnancy. It is a calcium channel blocker of the dihydropyridine class. It works by dilating peripheral arteries.
Nicardipine was patented in 1973 and first approved for medical use in 1981. It was approved in the United States in 1988. It is available as a generic medication. In the United Kingdom 4 weeks of medication costs the NHS about £10 as of 2021. In the United States this amount costs about 130 USD.
For angina or high blood pressure it is used at a dose of 20 to 30 mg three times per day.
Society and culture
The patent for both Cardene and Cardene SR expired in October 1995.
- "Nicardipine Monograph for Professionals". Drugs.com. Archived from the original on 21 September 2021. Retrieved 12 November 2021.
- Pope, J (10 October 2013). "Raynaud's phenomenon (primary)". BMJ clinical evidence. 2013: 1119. PMID 24112969.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 176. ISBN 978-0857114105.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 464. ISBN 9783527607495. Archived from the original on 2021-08-29. Retrieved 2021-09-18.
- "Nicardipine Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 22 September 2021. Retrieved 13 November 2021.
- Huang RI, Patel P, Walinsky P, et al. (November 2006). "Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention". Catheterization and Cardiovascular Interventions. 68 (5): 671–6. doi:10.1002/ccd.20885. PMID 17034064. S2CID 37071966.
- "Nicardipine at Medline PLus". Archived from the original on 2016-07-05. Retrieved 2021-09-18.